GlassScriptPhysician profile
Daniela P Lopez
NPI 1669211181
$1,289.11
in general payments reported to CMS, 2019-2025
14 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $184 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $280.47 | 2025 | Camzyos, Eliquis |
| Pfizer INC. | $253.23 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $250.51 | 2024-2025 | Verquvo |
| Boston Scientific Corporation | $112.09 | 2024-2025 | Watchman Flx, Watchman Access System |
| Novo Nordisk INC | $90.70 | 2025 | Wegovy, Ozempic |
| Esperion Therapeutics, INC. | $56.77 | 2024-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $50.09 | 2025 | |
| Novartis Pharmaceuticals Corporation | $41.49 | 2025 | |
| Scpharmaceuticals INC. | $34.42 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.62 | 2025 | Jardiance |
| Lilly USA, LLC | $33.48 | 2025 | Zepbound, Mounjaro |
| Kiniksa Pharmaceuticals International, Plc | $23.03 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $14.88 | 2024 | Farxiga |
| Tactile Systems Technology INC | $14.33 | 2024 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.